2008-07-09 23:57:07 -

- Aradigm Corporation (OTCBB: ARDM) (the "Company"), a specialty pharmaceutical company, today announced it will hold a business update conference call on Wednesday, July 16, 2008 at 11:00 a.m. Eastern (8:00 a.m. Pacific).

Aradigm's President and Chief Executive Officer Igor Gonda, Ph.D., and Company management will discuss details of the results and findings of the Company's recently concluded phase

2a clinical study in cystic fibrosis, and provide an update on other aspects of the Company's business. A question-and-answer session will follow prepared remarks.

To participate in the live call by telephone, please dial (800) 323-0845 from the U.S., and for international callers, please dial (706) 634-8407. A telephone replay will be available for 48 hours by dialing (800) 642-1687 from the U.S., or (706) 645-9291 for international callers, and entering reservation number 55246868.

Individuals interested in listening to the conference call via the Internet may do so by visiting www.aradigm.com. An archived presentation will be available on the Web site for 14 days.

About Aradigm

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. Current activities include partnered and self-initiated development programs addressing the treatment of cystic fibrosis, bronchiectasis, pulmonary hypertension, asthma and COPD, inhalation anthrax infections and smoking cessation.

More information about Aradigm can be found at www.aradigm.com.

Aradigm and the Aradigm Logo are registered trademarks of Aradigm Corporation.

SOURCE: Aradigm

Aradigm
Investor Relations, 510-265-8850/9370
or
Lippert/Heilshorn & Associates
Don Markley or Bruce Voss, 310-691-7100